Phase 1 – testing safety in a small group of people
Conditions:
Graves Disease
Sponsor: Biohaven Therapeutics Ltd.
trial.available_in:
БГ
Overview
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Who can participate
Key Inclusion Criteria:
1\. Participants must have serologically confirmed Graves' Disease.
Key Exclusion Criteria:
1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
2. History of treatment with radioactive iodine or thyroid surgery.
БГ